Assets measured at fair value
IE60
For assets and liabilities measured at fair value at the end of the reporting period, the IFRS requires quantitative disclosures about the fair value measurements for each class of assets and liabilities. An entity might disclose the following for assets to comply with paragraph 93(a) and (b) of the ifrs-full:
(CU in millions) | Fair value measurements at the end of the reporting period using | ||||||||||||
Description | 31/12/X9 | Quoted prices in active markets for identical assets (Level 1) | Significant other observable inputs (Level 2) | Significant unobservable inputs (Level 3) | Total gains (losses) | ||||||||
Recurring fair value measurements | |||||||||||||
Trading equity securities: | |||||||||||||
Real estate industry |
|
|
|
||||||||||
Oil and gas industry |
|
|
|||||||||||
Other |
|
|
|||||||||||
Total trading equity securities |
|
|
|
||||||||||
Other equity securities: | |||||||||||||
Financial services industry |
|
|
|||||||||||
Healthcare industry |
|
|
|
||||||||||
Energy industry |
|
|
|||||||||||
Private equity fund investments |
|
|
|||||||||||
Other |
|
|
|||||||||||
Total other equity securities |
|
|
|
||||||||||
Debt securities: | |||||||||||||
Residential mortgage-backed securities |
|
|
|
||||||||||
Commercial mortgage-backed securities |
|
|
|||||||||||
Collateralised debt obligations |
|
|
|||||||||||
Risk-free government securities |
|
|
|||||||||||
Corporate bonds |
|
|
|
||||||||||
Total debt securities |
|
|
|
|
|||||||||
Hedge fund investments: | |||||||||||||
Equity long/short |
|
|
|||||||||||
Global opportunities |
|
|
|||||||||||
High-yield debt securities |
|
|
|||||||||||
Total hedge fund investments |
|
|
|
||||||||||
Derivatives: | |||||||||||||
Interest rate contracts |
|
|
|||||||||||
Foreign exchange contracts |
|
|
|||||||||||
Credit contracts |
|
|
|||||||||||
Commodity futures contracts |
|
|
|||||||||||
Commodity forward contracts |
|
|
|||||||||||
Total derivatives |
|
|
|
|
|||||||||
Investment properties: | |||||||||||||
Commercial - Asia |
|
|
|||||||||||
Commercial - Europe |
|
|
|||||||||||
Total investment properties |
|
|
|||||||||||
Total recurring fair value measurements |
|
|
|
|
|||||||||
Non-recurring fair value measurements | |||||||||||||
Assets held for sale |
|
|
|||||||||||
Total non-recurring fair value measurements |
|
|
|||||||||||
(Note: A similar table would be presented for liabilities unless another format is deemed more appropriate by the entity.) |
Reconciliation of fair value measurements categorised within Level 3 of the fair value hierarchy
IE61
For recurring fair value measurements categorised within Level 3 of the fair value hierarchy, the IFRS requires a reconciliation from the opening balances to the closing balances for each class of assets and liabilities. An entity might disclose the following for assets to comply with paragraph 93(e) and (f) of the ifrs-full:
Fair value measurements using significant unobservable inputs (Level 3) | ||||||||||||||||||||||||
(CU in millions) | Other equity securities | Debt securities | Hedge fund investments | Derivatives | Investment properties | |||||||||||||||||||
Healthcare industry | Energy industry | Private equity fund | Residential mortgage-backed securities | Commercial mortgage-backed securities | Collateralised debt obligations | High-yield debt securities | Credit contracts | Asia | Europe | Total | ||||||||||||||
Opening balance |
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Transfers into Level 3 |
|
|
||||||||||||||||||||||
Transfers out of Level 3 | ( |
( |
||||||||||||||||||||||
Total gains or losses for the period | ||||||||||||||||||||||||
Included in profit or loss |
|
( |
( |
( |
|
|
|
|
( |
|||||||||||||||
Included in other comprehensive income |
|
|
|
|||||||||||||||||||||
Purchases, issues, sales and settlements | ||||||||||||||||||||||||
Purchases |
|
|
|
|
|
|
||||||||||||||||||
Issues | ||||||||||||||||||||||||
Sales | ( |
( |
( |
|||||||||||||||||||||
Settlements | ( |
( |
||||||||||||||||||||||
Closing balance |
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Change in unrealised gains or losses for the period included in profit or loss for assets held at the end of the reporting period |
|
( |
( |
( |
( |
|
|
|
( |
|||||||||||||||
(Note: A similar table would be presented for liabilities unless another format is deemed more appropriate by the entity.) |
IE62
Gains and losses included in profit or loss for the period (above) are presented in financial income and in non-financial income as follows:
(CU in millions) | Financial income | Non-financial income | ||||
Total gains or losses for the period included in profit or loss | ( |
|
||||
Change in unrealised gains or losses for the period included in profit or loss for assets held at the end of the reporting period | ( |
|
||||
(Note: A similar table would be presented for liabilities unless another format is deemed more appropriate by the entity.) |
Valuation techniques and inputs
IE63
For fair value measurements categorised within Level 2 and Level 3 of the fair value hierarchy, the IFRS requires an entity to disclose a description of the valuation technique(s) and the inputs used in the fair value measurement. For fair value measurements categorised within Level 3 of the fair value hierarchy, information about the significant unobservable inputs used must be quantitative. An entity might disclose the following for assets to comply with the requirement to disclose the significant unobservable inputs used in the fair value measurement in accordance with paragraph 93(d) of the ifrs-full:
Quantitative information about fair value measurements using significant unobservable inputs (Level 3) | |||||||||||
(CU in millions) | |||||||||||
Description | Fair value at 31/12/X9 | Valuation technique(s) | Unobservable input | Range (weighted average) | |||||||
Other equity securities: | |||||||||||
Healthcare industry |
|
Discounted cash flow | weighted average cost of capital |
|
|||||||
long-term revenue growth rate |
|
||||||||||
long-term pre-tax operating margin |
|
||||||||||
discount for lack of marketability |
|
||||||||||
control premium |
|
||||||||||
Market comparable companies | EBITDA multiple |
|
|||||||||
revenue multiple |
|
||||||||||
discount for lack of marketability |
|
||||||||||
control premium |
|
||||||||||
Energy industry |
|
Discounted cash flow | weighted average cost of capital |
|
|||||||
long-term revenue growth rate |
|
||||||||||
long-term pre-tax operating margin |
|
||||||||||
discount for lack of marketability |
|
||||||||||
control premium |
|
||||||||||
Market comparable companies | EBITDA multiple |
|
|||||||||
revenue multiple |
|
||||||||||
discount for lack of marketability |
|
||||||||||
control premium |
|
||||||||||
Private equity fund investments |
|
Net asset value | n/a |
|
|||||||
Debt securities: | |||||||||||
Residential mortgage-backed securities |
|
Discounted cash flow | constant prepayment rate |
|
|||||||
probability of default |
|
||||||||||
loss severity |
|
||||||||||
Commercial mortgage-backed securities |
|
Discounted cash flow | constant prepayment rate |
|
|||||||
probability of default |
|
||||||||||
loss severity |
|
||||||||||
Collateralised debt obligations |
|
Consensus pricing | offered quotes |
|
|||||||
comparability adjustments (%) | - |
||||||||||
Hedge fund investments: | |||||||||||
High-yield debt securities |
|
Net asset value | n/a |
|
|||||||
Derivatives: | |||||||||||
Credit contracts |
|
Option model | annualised volatility of credit |
|
|||||||
counterparty credit risk |
|
||||||||||
own credit risk |
|
||||||||||
Investment properties: | |||||||||||
Commercial - Asia |
|
Discounted cash flow | long-term net operating income margin |
|
|||||||
cap rate |
|
||||||||||
Market comparable approach | price per square metre (USD) | $ |
|||||||||
Commercial - Europe |
|
Discounted cash flow | long-term net operating income margin |
|
|||||||
cap rate |
|
||||||||||
Market comparable approach | price per square metre (EUR) | € |
|||||||||
(Note: A similar table would be presented for liabilities unless another format is deemed more appropriate by the entity.) |
Copyright © 2021 IFRS Foundation
All rights reserved. Reproduction and use rights are strictly limited. Please contact the Foundation for further details at licences@ifrs.org.
The Foundation has trade marks registered around the world (Marks) including ‘IAS®’, ‘IASB®’, the IASB® logo, ‘IFRIC®’, ‘IFRS®’, the IFRS® logo, ‘IFRS for SMEs®’, the IFRS for SMEs® logo, ‘IFRS Taxonomy’, ‘International Accounting Standards®’, ‘International Financial Reporting Standards®’, the ‘Hexagon Device’, ‘NIIF®’ and ‘SIC®’. Further details of the Foundation’s Marks are available from the Foundation on request.